Free Trial
NASDAQ:TYRA

Tyra Biosciences (TYRA) Stock Price, News & Analysis

Tyra Biosciences logo
$15.63 +1.20 (+8.32%)
As of 01/3/2025 05:39 PM Eastern

About Tyra Biosciences Stock (NASDAQ:TYRA)

Key Stats

Today's Range
$14.53
$15.65
50-Day Range
$13.90
$19.89
52-Week Range
$11.24
$29.60
Volume
203,528 shs
Average Volume
170,764 shs
Market Capitalization
$790.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.00
Consensus Rating
Buy

Company Overview

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Tyra Biosciences Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
49th Percentile Overall Score

TYRA MarketRank™: 

Tyra Biosciences scored higher than 49% of companies evaluated by MarketBeat, and ranked 570th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Tyra Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Tyra Biosciences has only been the subject of 3 research reports in the past 90 days.

  • Read more about Tyra Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Tyra Biosciences are expected to decrease in the coming year, from ($1.57) to ($2.04) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Tyra Biosciences is -9.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Tyra Biosciences is -9.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Tyra Biosciences has a P/B Ratio of 3.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    8.24% of the float of Tyra Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Tyra Biosciences has a short interest ratio ("days to cover") of 7.7.
  • Change versus previous month

    Short interest in Tyra Biosciences has recently increased by 25.87%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Tyra Biosciences does not currently pay a dividend.

  • Dividend Growth

    Tyra Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.24% of the float of Tyra Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Tyra Biosciences has a short interest ratio ("days to cover") of 7.7.
  • Change versus previous month

    Short interest in Tyra Biosciences has recently increased by 25.87%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Tyra Biosciences has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Tyra Biosciences this week, compared to 3 articles on an average week.
  • Search Interest

    Only 1 people have searched for TYRA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Tyra Biosciences insiders have sold 1,102.00% more of their company's stock than they have bought. Specifically, they have bought $152,000.00 in company stock and sold $1,827,047.00 in company stock.

  • Percentage Held by Insiders

    15.40% of the stock of Tyra Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    84.14% of the stock of Tyra Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Tyra Biosciences' insider trading history.
Receive TYRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tyra Biosciences and its competitors with MarketBeat's FREE daily newsletter.

TYRA Stock News Headlines

#1 Crypto of 2025
Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... But today, Chris is now making the biggest crypto call of his ENTIRE career…
The Take On Tyra Biosciences
Piper Sandler Remains a Buy on Tyra Bioscience (TYRA)
See More Headlines

TYRA Stock Analysis - Frequently Asked Questions

Tyra Biosciences' stock was trading at $13.90 at the start of the year. Since then, TYRA stock has increased by 12.4% and is now trading at $15.63.
View the best growth stocks for 2025 here
.

Tyra Biosciences, Inc. (NASDAQ:TYRA) announced its earnings results on Thursday, November, 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.01.

Tyra Biosciences (TYRA) raised $100 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share.

Shares of TYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tyra Biosciences investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC), Waste Connections (WCN), AUO (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
11/07/2024
Today
1/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TYRA
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$31.00
High Stock Price Target
$33.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+98.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-69,130,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.74 per share

Miscellaneous

Free Float
42,810,000
Market Cap
$790.92 million
Optionable
Optionable
Beta
1.01
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:TYRA) was last updated on 1/4/2025 by MarketBeat.com Staff
From Our Partners